News

Law

Asset Management

Investment Banking

Wealth

Hedge Funds

People

Newsletters

Events

Lists

YM Biosciences completes first dual listing on AIM and TSE

YM Biosciences, a Canadian firm which develops drugs used in the treatment of cancer, has become the first company to dual list on London's Alternative Investment Market (AIM) and the Toronto Stock Exchange (TSE).

It is only the second firm to mount simultaneous initial public offerings in London and Toronto, following Hemlo Gold Mines in 1987, according to Dealogic.

WSJ Logo